Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –– ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®â–¼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –– ...
Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...
(MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a ...